2,091 reports of this reaction
1.2% of all MEPOLIZUMAB reports
#19 most reported adverse reaction
OBSTRUCTIVE AIRWAYS DISORDER is the #19 most commonly reported adverse reaction for MEPOLIZUMAB, manufactured by GlaxoSmithKline LLC. There are 2,091 FDA adverse event reports linking MEPOLIZUMAB to OBSTRUCTIVE AIRWAYS DISORDER. This represents approximately 1.2% of all 173,706 adverse event reports for this drug.
Patients taking MEPOLIZUMAB who experience obstructive airways disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OBSTRUCTIVE AIRWAYS DISORDER is a less commonly reported adverse event for MEPOLIZUMAB, but still significant enough to appear in the safety profile.
In addition to obstructive airways disorder, the following adverse reactions have been reported for MEPOLIZUMAB:
The following drugs have also been linked to obstructive airways disorder in FDA adverse event reports:
OBSTRUCTIVE AIRWAYS DISORDER has been reported as an adverse event in 2,091 FDA reports for MEPOLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OBSTRUCTIVE AIRWAYS DISORDER accounts for approximately 1.2% of all adverse event reports for MEPOLIZUMAB, making it a notable side effect.
If you experience obstructive airways disorder while taking MEPOLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.